EP Patent

EP2508170A1 — Liposome of irinotecan or its hydrochloride and preparation method thereof

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2012-10-10 · 14y expired

What this patent protects

A liposome of irinotecan or its hydrochloride and its preparation method are disclosed. The liposome comprises irinotecan or its hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of cholesterol to neutral phospholipid is 1:3-5. Said liposome is prepare…

USPTO Abstract

A liposome of irinotecan or its hydrochloride and its preparation method are disclosed. The liposome comprises irinotecan or its hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of cholesterol to neutral phospholipid is 1:3-5. Said liposome is prepared by ion gradient method.

Drugs covered by this patent

Patent Metadata

Patent number
EP2508170A1
Jurisdiction
EP
Classification
—
Expires
2012-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.